132 LeeY
Details on used samples number, number of aliquots and technical replicates are described in Supplementary Tables 2 and 3
Under this approach, an ACO prohibited from participating in the ENHANCED track because it has fewer than 5,000 assigned beneficiaries in BY1, BY2, or both, may enter an agreement period beginning on or after January 1, 2027, in the BASIC track, at a level of risk and potential reward otherwise determined in accordance with the proposed requirements of new 425.600(h), as follows: An ACO determined to be inexperienced with performance-based risk Medicare ACO initiatives may enter the BASIC track's glide path at any of the levels of risk and potential reward, Levels A through E (if eligible in accordance with the proposed requirements at new 425.600(h)(1)), or BASIC track Level E for all performance years of the agreement period
78 HP 160 CAGRILINTIDE Long-Acting Amylin Analog ALIASES Cagrilintide, AM833, long-acting amylin analog CLASS Synthetic amylin analog once-weekly dual amylin/calcitonin agonist FORMULA CHNO (approx) SEQUENCE 37-residue amylin analog with C20-fatty-acid albumin tether HALF-LIFE ~7 days (once-weekly dosing) ROUTES Subcutaneous (Phase 2/3 clinical) MECHANISM OF ACTION Long-acting amylin analog
